Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors

IntroductionGlioblastoma (GBM), the most lethal primary brain malignancy, is divided into histological (hist-GBM) and molecular (mol-GBM) subtypes according to the 2021 World Health Organization classification of central nervous system tumors. This study aimed to characterize the clinical, radiologi...

Full description

Bibliographic Details
Main Authors:	Xiaopeng Guo, Lingui Gu, Yilin Li, Zhiyao Zheng, Wenlin Chen, Yaning Wang, Yuekun Wang, Hao Xing, Yixin Shi, Delin Liu, Tianrui Yang, Yu Xia, Junlin Li, Jiaming Wu, Kun Zhang, Tingyu Liang, Hai Wang, Qianshu Liu, Shanmu Jin, Tian Qu, Siying Guo, Huanzhang Li, Yu Wang, Wenbin Ma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Oncology
Subjects:	glioblastoma histological glioblastoma molecular glioblastoma molecular alteration chromosome copy number variation
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1200815/full

Similar Items

Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors
by: Xiaopeng Guo, et al.
Published: (2023-03-01)

Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors
by: Hai Wang, et al.
Published: (2024-02-01)

Spotlights on adult patients with pediatric-type diffuse gliomas in accordance with the 2021 WHO classification of CNS tumors
by: Wenlin Chen, et al.
Published: (2023-05-01)

Characteristic analysis and identification of novel molecular biomarkers in elderly glioblastoma patients using the 2021 WHO Classification of Central Nervous System Tumors
by: Yaning Wang, et al.
Published: (2023-06-01)

An online survival predictor in glioma patients using machine learning based on WHO CNS5 data
by: Liguo Ye, et al.
Published: (2023-05-01)

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study
by: Yuekun Wang, et al.
Published: (2024-07-01)

Novel insight into histological and molecular astrocytoma, IDH‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors
by: Wenlin Chen, et al.
Published: (2023-09-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
by: Shanmu Jin, et al.
Published: (2024-03-01)

Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma
by: Binghao Zhao, et al.
Published: (2023-04-01)

TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study
by: Hao Xing, et al.
Published: (2025-01-01)

The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis
by: Yixin Shi, et al.
Published: (2024-06-01)

Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review
by: Sarah Travers, et al.
Published: (2021-04-01)

Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors
by: Yixin Shi, et al.
Published: (2021-05-01)

Chrysomycin A Inhibits the Proliferation, Migration and Invasion of U251 and U87-MG Glioblastoma Cells to Exert Its Anti-Cancer Effects
by: Dong-Ni Liu, et al.
Published: (2022-09-01)

Impact of Rural vs. Urban Residence on Survival Rates of Patients with Glioblastoma: A Tertiary Care Center Experience
by: Ali Alwadei, et al.
Published: (2022-09-01)

Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma
by: Yuekun Wang, et al.
Published: (2023-04-01)

Pitfalls in the diagnosis of glioblastoma
by: Bica Dorin, et al.
Published: (2023-03-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells
by: Michael S. Petronek, et al.
Published: (2024-01-01)

Artificial neural network identified a 20‐gene panel in predicting immunotherapy response and survival benefits after anti‐PD1/PD‐L1 treatment in glioblastoma patients
by: Yaning Wang, et al.
Published: (2024-05-01)

Immunomodulation - hope for patient with Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2018-09-01)

Glioblastoma multiforme - disease overview considering sports and neurorehabilitation
by: Monika Niedźwiedzka, et al.
Published: (2024-10-01)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
by: Giuseppe Stragliotto, et al.
Published: (2020-09-01)

A reference for selecting an appropriate method for generating glioblastoma organoids from the application perspective
by: Jing Liang, et al.
Published: (2024-09-01)

Utility of the Cerebral Organoid Glioma ‘GLICO’ Model for Screening Applications
by: Freya R. Weth, et al.
Published: (2022-12-01)

The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma
by: Hao Wang, et al.
Published: (2024-09-01)

A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art
by: Mateusz Pinkiewicz, et al.
Published: (2022-09-01)

Worldwide productivity and research trend of publications concerning glioma-associated macrophage/microglia: A bibliometric study
by: Yu-yang Liu, et al.
Published: (2022-12-01)

Pre-Treatment and Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Prognostic Value of Glioblastoma: A Meta-Analysis
by: Xin Guo, et al.
Published: (2022-05-01)

The antiferroptotic role of TRIM7: Molecular mechanism and synergistic effect with temozolomide
by: Luyao Wang, et al.
Published: (2023-08-01)

Identification of a Metabolism-Related Risk Signature Associated With Clinical Prognosis in Glioblastoma Using Integrated Bioinformatic Analysis
by: Zheng He, et al.
Published: (2020-09-01)

Cytotoxic effects of Methoxy-substituted Chalcones on glioblastoma stem cells: Computational target prediction and therapeutic insights
by: Eduardo A. Veliz, et al.
Published: (2025-03-01)

Practice Patterns for Managing Recurrent Glioblastoma Multiforme
by: Jitin Bajaj, et al.
Published: (2024-03-01)

Caspase-3 and Bcl-2 expression in glioblastoma: an immunohistochemical study Expressão de caspase-3 e Bcl-2 em glioblastomas: um estudo imunohistoquímico
by: Luís Fernando Tirapelli, et al.
Published: (2010-08-01)

Glioblastoma multiforme associated with arteriovenous malformation: A case report and literature review
by: Thara Tunthanathip, et al.
Published: (2020-01-01)

Identification of candidate biomarkers for GBM based on WGCNA
by: Qinghui Sun, et al.
Published: (2024-05-01)

Corrigendum: MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways
by: Xu Zhang, et al.
Published: (2022-04-01)

MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways
by: Xu Zhang, et al.
Published: (2021-01-01)

Leptomeningeal neuraxis relapse in glioblastoma is an uncommon but not rare event associated with poor outcome
by: Eric Wegener, et al.
Published: (2023-09-01)

Adenoid glioblastoma
by: Cui-yun SUN, et al.
Published: (2018-02-01)